Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Companies Promote Earlier Treatment For Allergies

This article was originally published in PharmAsia News

Executive Summary

The allergy season does not officially start until March, however, several pharmaceutical companies including GlaxoSmithKline have started PR campaigns advocating earlier preparation and treatment.One in five people in Japan suffers from allergies. Due to an exceptionally hot summer last year, pollen levels this year in some areas are estimated to be three times greater than average. In January, when early pollen emission began, GSK started distributing brochures on preliminary allergy treatment to medical facilities. GSK advocated that patients seek expert advice and take allergy prescription drugs earlier and take different doses according to symptom development, instead of waiting for the arrival of peak allergy season.Sinus infection drugs such as second generation antihistamine drugs have been central to early treatment. Kyowa Hakko Kogyo says that market share for the drugs have increased by 18 percent from 2000 to 2006. (Click here for more

You may also be interested in...



Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.

US FDA Investigators Focusing Inspections On Aseptic Processing Operations

US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel